Seres Therapeutics/$MCRB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Seres Therapeutics
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Ticker
$MCRB
Sector
Primary listing
Employees
66
Headquarters
Website
MCRB Metrics
BasicAdvanced
$77m
-
-$5.17
0.12
-
Price and volume
Market cap
$77m
Beta
0.12
52-week high
$29.98
52-week low
$5.31
Average daily volume
91k
Financial strength
Current ratio
1.646
Quick ratio
1.554
Long term debt to equity
262.78
Total debt to equity
303.781
Profitability
EBITDA (TTM)
-83.804
Gross margin (TTM)
-4,560.07%
Net profit margin (TTM)
-4,088.84%
Operating margin (TTM)
-7,640.98%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-38.88%
Return on equity (TTM)
-121.87%
Valuation
Price to revenue (TTM)
62.847
Price to book
2.87
Price to tangible book (TTM)
2.87
Price to free cash flow (TTM)
-1.701
Free cash flow yield (TTM)
-58.78%
Free cash flow per share (TTM)
-4.667
Growth
Earnings per share change (TTM)
-157.67%
3-year revenue growth (CAGR)
-39.24%
10-year revenue growth (CAGR)
-8.24%
3-year earnings per share growth (CAGR)
-51.55%
10-year earnings per share growth (CAGR)
-18.92%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs